Company Overview - Hanbo High-tech (SZ 301321) announced on December 1 that its fourth board meeting was held to discuss the establishment of a joint venture with professional investment institutions [1] - As of the report, Hanbo High-tech has a market capitalization of 3 billion yuan [1] Revenue Composition - For the year 2024, Hanbo High-tech's revenue composition is as follows: 95.24% from the backlight display module industry and 4.76% from other businesses [1]

证券代码：301321 证券简称：翰博高新 公告编号：2025-056 翰博高新材料（合肥）股份有限公司 第四届董事会第二十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 2、会议于 2025 年 12 月 1 日在安徽省合肥市新站区大禹路 699 号公司会议 室以现场与通讯结合的方式召开。 3、本次董事会会议应出席的董事人数 7 人，实际参加的董事人数 7 人。本 次董事会会议由董事长王照忠先生主持，公司高级管理人员列席本次董事会会议。 4、本次董事会会议的召集召开符合有关法律、行政法规、部门规章、规范 性文件及《公司章程》的规定。 二、董事会会议审议情况 经与会董事投票表决，审议通过了如下议案： 审议通过《关于与专业投资机构共同投资设立合资公司的议案》 表决结果：7 票同意，0 票反对，0 票弃权；获全体董事一致通过。 具体内容详见公司同日于巨潮资讯网（http://www.cninfo.com.cn）披露的 《关于与专业投资机构共同投资设立合资公司的公告》。 三、备查文件 第四届董事会第二十二次会议决议。 1、翰 ...

证券代码：301321 证券简称：翰博高新 公告编号：2025-057 翰博高新材料（合肥）股份有限公司 关于与专业投资机构共同投资设立合资公司的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、对外投资概况 翰博高新材料（合肥）股份有限公司（以下简称"公司"或"翰博高新"）于 2025年12月1日召开第四届董事会第二十二次会议审议通过《关于与专业投资机构共 同投资设立合资公司的议案》。为科技创新、战略布局高附加值产品，实现合作共 赢之目的，公司与北京芯进科技有限公司（以下简称"北京芯进"）、青岛初芯瑞 伯创业投资基金合伙企业（有限合伙）（以下简称"初芯瑞伯基金"）共同投资设 立合资公司（暂定名：合肥芯东进新材料科技有限公司，最终以市场监督管理部门 核定为准，以下简称"标的公司"）。由其作为控股平台载体，联合其他股东，拟 投资/收购外资在华湿电子化学品项目（以下简称"拟投项目"）。 标的公司目标认缴出资总额为44,000万元，公司拟以自有/自筹资金认缴出资人 民币20,000万元，持有标的公司45.4545%股权；北京芯进拟以自有/自筹资金认缴出 资人 ...

（编辑 任世碧） 证券日报网讯 11月28日晚间，翰博高新发布公告称，公司于近日接到公司控股股东王照忠先生通知， 获悉其将持有的公司部分股份办理了质押，相关手续已办理完毕，本次质押数量为17，000，000股。 ...

Core Viewpoint - The company, Hanbo High-tech (SZ 301321), announced a share pledge by its controlling shareholder, Wang Zhaozhong, involving 17 million shares, which raises concerns about the financial stability of the company [1] Group 1: Share Pledge Details - Wang Zhaozhong has pledged 17 million shares, with a total of 19.61 million shares pledged by Hanbo Holdings Group, representing 100% of its holdings [1] - Hefei Wangshi Hanbo Technology Co., Ltd. has pledged 3.5 million shares, accounting for 21.07% of its holdings [1] Group 2: Revenue Composition - For the year 2024, the revenue composition of Hanbo High-tech is projected to be 95.24% from the backlight display module industry and 4.76% from other businesses [1] Group 3: Market Capitalization - As of the announcement, the market capitalization of Hanbo High-tech is 3 billion yuan [1]

证券代码：301321 证券简称：翰博高新 公告编号：2025-055 翰博高新材料（合肥）股份有限公司 关于控股股东部分股份质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 翰博高新材料（合肥）股份有限公司（以下简称"公司"）于近日接到公司 控股股东王照忠先生通知，获悉其将持有的公司部分股份办理了质押，相关手续 已办理完毕。具体事项如下： | | 是否为控股 | | 占其所 | 占公司 | | 是否 | | 质押 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | 股东或第一 | 本次质押数 | 持股份 | 总股本 | 是否为 | 为补 | 质押起始日 | 到期 | 质权人 | 质押 | | 名称 | 大股东及其 | 量（股） | 比例 | 比例 | 限售股 | 充质 | | 日 | | 用途 | | | 一致行动人 | | (%) | (%) | | 押 | | | 中国工商 | | | 王照忠 | 是 | 17,000,000 | 33 ...

Core Viewpoint - The partnership between Hanbo High-Tech and LG Display marks a significant milestone in the company's internationalization strategy, enhancing its presence in the high-end display module market and improving its global supply chain system [5][6]. Group 1: Company Overview - Hanbo High-Tech is a comprehensive solution provider for semiconductor display panel backlight modules and key components, with products including backlight display modules, light guide plates, precision structural parts, and optical materials [4]. - The company's products are widely applicable in various end-user fields such as laptops, tablets, desktop displays, automotive displays, medical monitors, industrial control displays, and VR [4]. Group 2: Production Capacity - Hanbo High-Tech's subsidiary in Vietnam, Hanwei Technology (Vietnam) Co., Ltd., officially opened in September 2023, with plans for phased construction, aiming for full automation certification and mass production of backlight sources and LCM products by 2025 [4]. - The company also initiated the construction of a precision structural parts base in Ho Chi Minh City in July 2023, expected to be operational by the end of 2025, focusing on precision stamping, injection molding, and in-mold injection production [4]. Group 3: Financial Performance - In the first three quarters of 2025, the company achieved operating revenue of 2.424 billion yuan, a year-on-year increase of 44.06%, with a net profit attributable to shareholders of -8.7869 million yuan [4]. - In the third quarter, the operating revenue reached 870 million yuan, up 33.34% year-on-year, with a net profit attributable to shareholders of 17.6625 million yuan, reflecting a significant year-on-year growth of 153.33% [4].

Core Viewpoint - Hanbo High-tech stated on November 14 that it ensures all investors receive company information equally by disclosing shareholder information at specific points in its regular reports [2] Group 1 - The company engages with investors through an interactive platform to address inquiries [2] - The company emphasizes transparency in its communication with shareholders [2]

Core Insights - The light guide plate (LGP) industry in China is experiencing significant growth, driven by advancements in consumer electronics and emerging industries, with market size expected to reach 10.66 billion yuan in 2024 and exceed 11.17 billion yuan in 2025 [1][9][10] - The industry has established a complete supply chain, with domestic production increasing, particularly in high-end materials, while the competition is characterized by local leaders excelling in niche markets and international players maintaining a high-end positioning [1][5][12] Industry Overview - Light guide plates are optical components that convert line light sources into uniform surface light sources, utilizing optical-grade PMMA or PC materials [2][3] - The industry is segmented by manufacturing processes, application scenarios, and substrate types, catering to diverse market demands [3][4] Supply Chain Structure - The Chinese light guide plate industry has a clear and collaborative supply chain, with upstream relying on optical-grade materials and downstream applications expanding into automotive electronics and AR/VR [5][7] - The market is dominated by display panels, lighting, and automotive electronics, which together account for over 97% of market demand [7][9] Current Market Analysis - The market for light guide plates is expanding due to the increasing demand for thinner and higher transparency products in consumer electronics and the rapid growth of automotive displays [9][11] - The overall market size is projected to grow steadily, supported by the continuous influx of LCD panel production capacity into mainland China [10][11] Competitive Landscape - The competition in the light guide plate industry is marked by local leaders focusing on specific segments while international companies maintain a stronghold in high-end optical materials [12][14] - Key players like Tianlu Technology and Nanjiguang are leading in the mid-to-large size segments, while companies like Crystal Optoelectronics and Weiwang Technology are focusing on high-value areas such as AR/VR [12][14] Future Development Trends - The industry is expected to focus on three main areas: technological upgrades, expansion into new application scenarios, and deeper industry integration [15][18] - Technological advancements will drive the shift towards ultra-thin, high-precision, and environmentally friendly materials, while demand will increasingly come from diverse sectors beyond traditional consumer electronics [16][17] - The integration of industry clusters will enhance collaboration and competitiveness among domestic companies, accelerating the process of domestic substitution in high-end products [18]

Core Viewpoint - The article discusses the contrasting experiences of Chinese and foreign pharmaceutical companies in the innovative drug market, particularly focusing on the emergence of dual-target weight loss drugs and the financial implications of drug licensing agreements [4][8]. Group 1: Market Dynamics - The dual-target weight loss drug "Tirzepatide," developed by Eli Lilly, generated sales of $16.4 billion last year due to its ability to mimic two natural hormones, GLP-1 and GIP, effectively suppressing appetite and controlling blood sugar [4][6]. - In contrast, Chinese company Hansoh Pharmaceutical's HS-20094, also a dual-target drug, was licensed to Regeneron for an upfront payment of only $80 million, highlighting the disparity in financial returns between Chinese and foreign firms [6][11]. Group 2: Drug Development Challenges - The pharmaceutical industry operates under a "three tens" rule: 10 years of development, $1 billion investment, and a 10% success rate, indicating the high risks associated with innovative drug development [12][13]. - Innovative drugs are categorized into two types: First-in-class, which are groundbreaking treatments, and Fast Follow, which modify existing drug structures without infringing on patents [14][17]. Group 3: Competitive Landscape - Chinese pharmaceutical companies have made significant strides, with their first-in-class drugs accounting for 24% of the global pipeline, second only to the United States [19]. - The article notes that multinational corporations are increasingly seeking to acquire Chinese innovative drugs due to the expiration of their own patents and the high costs of internal R&D [21]. Group 4: R&D Efficiency - Chinese companies excel in the speed of drug development, particularly in patient recruitment for clinical trials, which can take significantly less time compared to the U.S. [22]. - The rise of the CRO (Contract Research Organization) industry in China has created a large pool of skilled researchers familiar with international standards, enhancing the country's R&D capabilities [25][27]. Group 5: Globalization of Chinese Pharma - The article emphasizes that the ultimate goal for Chinese innovative drug companies is to enter global markets, as the potential market of 7 billion people far exceeds that of 1.4 billion in China [38]. - The licensing-out model allows Chinese companies to secure upfront payments to fund further R&D while granting multinational firms rights to sell their drugs in other markets [39]. Group 6: Social Responsibility and Challenges - The article highlights the social responsibility of pharmaceutical companies, citing the case of Betta Pharmaceuticals, which provided free life-saving drugs worth nearly $13 billion to patients [40]. - However, it also points out the challenges faced by companies like Betta, which have encountered product shortages and financial difficulties, raising questions about the sustainability of their charitable initiatives [42].